GlassScriptPhysician profile
Mario Alberto Garza
NPI 1194719666
$5,494.72
in general payments reported to CMS, 2019-2025
35 companies · $906 in 2025
The $906 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $177 · 2021: $595 · 2022: $896 · 2023: $1,416 · 2024: $1,121 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,442.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,364.40 | 2019-2025 | |
| Janssen Biotech, INC. | $641.85 | 2020-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $449.71 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $367.76 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $207.28 | 2019-2025 | |
| Genzyme Corporation | $171.22 | 2022-2025 | |
| Pfizer INC. | $161.23 | 2021-2024 | |
| Evoke Pharma, INC. | $106.06 | 2023 | Gimoti |
| Lilly USA, LLC | $105.12 | 2024-2025 | Omvoh |
| Novartis Pharmaceuticals Corporation | $103.92 | 2020 | |
| Braintree Laboratories, INC. | $87.64 | 2022-2024 | Suflave, Sutab |
| Ardelyx, INC. | $79.19 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $55.63 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.54 | 2023-2024 | Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $51.26 | 2022-2024 | Dupixent |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $48.67 | 2024 | Bylvay |
| Cook Medical LLC | $42.86 | 2025 | Hemospray |
| Horizon Therapeutics Plc | $40.16 | 2019-2020 | |
| Olympus America INC. | $38.14 | 2021 | |
| Madrigal Pharmaceuticals | $38.04 | 2024 | Resmetirom |
| Amag Pharmaceuticals, INC. | $33.61 | 2021-2022 | |
| Abbott Laboratories | $32.47 | 2025 | Id Now Instrument |
| Merck Sharp & Dohme LLC | $29.87 | 2024 | Zerbaxa, Dificid |
| Qol Medical, LLC | $29.03 | 2019-2024 | Sucraid |
| Phathom Pharmaceuticals, INC. | $28.84 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $23.21 | 2025 | Vegzelma |
| Novo Nordisk INC | $19.00 | 2025 | Wegovy |
| Ucb, INC. | $17.20 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.20 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.17 | 2019 | |
| Redhill Biopharma INC. | $13.09 | 2023 | Talicia |
| Ferring Pharmaceuticals INC. | $12.47 | 2019 | |
| Endogastric Solutions, INC | $8.16 | 2023 | Esophyx |
| Romark Laboratories, Lc | $6.72 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$85,307.35 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Garza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.